drugset / Trial / NCT05028829
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Phase 2
Recruiting
60 enrolled
Raymond Chung
University of Texas Southwestern Medical Center · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Timeline
- Start
- 2023-05-10
- Primary completion
- 2026-12-31
- Completion
- 2031-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 20 mg | Oral |